Description: Adaptimmune Therapeutics plc, a clinical-stage biopharmaceutical company, provides novel cell therapies primarily to cancer patients in the United States and the United Kingdom. It develops SPEARHEAD-1 that is in phase II clinical trials with ADP-A2M4 for synovial sarcoma; SURPASS-3 that is in phase II clinical trial with ADP-A2M4CD8 for people with platinum resistant ovarian cancer; and SURPASS that is in phase I clinical trials in patients with head and neck, and urothelial cancers. The company has strategic collaboration and license agreement with Genentech, Inc. and F. Hoffman-La Roche Ltd to develop personalized allogeneic and allogeneic T-cell therapies; research, collaboration, and license agreement with Universal Cells, Inc.; third-party collaborations with Noile-Immune and Alpine Immune Sciences; and strategic alliance agreement with the MD Anderson Cancer Center. Adaptimmune Therapeutics plc was founded in 2008 and is headquartered in Abingdon, the United Kingdom.
Home Page: www.adaptimmune.com
60 Jubilee Avenue
Abingdon,
OX14 4RX
United Kingdom
Phone:
44 12 3543 0000
Officers
| Name | Title |
|---|---|
| Mr. Adrian G. Rawcliffe | CEO, Principal Accounting Officer & Director |
| Dr. Helen Katrina Tayton-Martin MBA, Ph.D. | Co-Founder & Chief Business & Strategy Officer |
| Mr. Gavin Hilary James Wood ACA, BA (Hons) | Chief Financial Officer |
| Mr. William C. A. Bertrand Jr., Esq., J.D. | COO & Chief Compliance Officer |
| Dr. Elliot Norry B.A., M.D. | Chief Medical Officer |
| Ms. Joanna Brewer Ph.D. | Chief Scientific Officer |
| Dr. Juli P. Miller Ph.D. | VP of Corporate Affairs & Investor Relations |
| Ms. Kerry Sharp | Senior VP & General Council |
| Ms. Dana Lynch | Senior Director of Corporate Communications |
| Mr. John Lunger | Chief Patient Supply Officer |
Exchange: F
Country: DE : Germany
Currency: Euro (€)
| GIC Sector: | Health Care |
|---|---|
| GIC Group: | Pharmaceuticals, Biotechnology & Life Sciences |
| GIC Industry: | Biotechnology |
| GIC Sub-Industry: | Biotechnology |
| Forward PE: | 0 |
|---|---|
| Trailing PE: | 0 |
| Price-to-Book MRQ: | 2.0317 |
| Price-to-Sales TTM: | 1.1601 |
| IPO Date: | |
| Fiscal Year End: | December |
| Full Time Employees: | 449 |